Small Team Focus With a published workforce of one, Anchiano Therapeutics presents a potential outsourcing or CRO collaboration opportunity for specialized oncology R&D services, enabling them to leverage external capabilities to advance programs without expanding headcount.

Early Stage Funding Anchiano has secured funding of around $32 million and has prior IPO activity, indicating appetite for strategic partnerships, licensing, or co-development deals to accelerate pipeline programs and reduce time to clinic.

Partnership History Historical collaborations with ADT Pharmaceuticals and Chemomab suggest openness to joint development and merger opportunities; structured deal options could include licensing, milestone-based collaborations, or asset co-development to de-risk internal capacity.

Pipeline Signals Attention to small-molecule oncology targets such as RAS and beta-catenin pathways indicates potential for high-value opportunities in translational research tools, assay development, and preclinical services aligned to challenging oncogenic targets.

Market Positioning As a Nasdaq-listed biotech with modest revenue, Anchiano may be seeking strategic buyers or partners to bolster commercial infrastructure, manufacturing, or late-stage development capabilities through out-licensing or collaboration to reach commercialization milestones.